Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7500935

CN(C)C(N)=O.O=C(O)C(F)(F)F

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
ALDH1A1 P00352 3/20 0.32
TSHR P16473 2/20 0.32
ACHE P22303 1/20 0.32
F2 P00734 1/20 0.31
F11 P03951 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
DPP4 P27487 2/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP9 Q86TI2 1/20 0.30
DPP7 Q9UHL4 1/20 0.30
LMNA P02545 1/20 0.30
ALOX15 P16050 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23043745 1.00 NOS1 (0.34) NOS1NOS2ALDH1A1TSHRACHE
Trifluoroacetamide SCHEMBL27765517 0.86 ALDH1A1 (0.33) ALDH1A1TSHRLMNAALOX15BLM
Trifluoroacetic Acid SCHEMBL3591146 0.82 ALDH1A1 (0.39) NOS1NOS2ALDH1A1TSHRL3MBTL1
Hydrogen Peroxide SCHEMBL4372518 0.82
Trifluoroacetic Acid SCHEMBL27766077 0.80 MAPT (0.34) ALDH1A1TSHRL3MBTL1PMP22
Trifluoroacetic Acid SCHEMBL5744812 0.79 LMNA (0.53) NOS1NOS2ALDH1A1TSHRACHE
Trifluoroacetic Acid SCHEMBL22557988 0.79 LMNA (0.53) NOS1NOS2ALDH1A1TSHRACHE
Trifluoroacetic Acid SCHEMBL937102 0.79 LMNA (0.53) NOS1NOS2ALDH1A1TSHRACHE
Trifluoroacetic Acid SCHEMBL29921600 0.79 LMNA (0.53) NOS1NOS2ALDH1A1TSHRACHE
Trifluoroacetic Acid SCHEMBL27529311 0.79 ALDH1A1 (0.37) ALDH1A1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
EP-2509602-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-10-17 EP disclosed
EP-1263725-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2001062729-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 NOS1 4405/4885NOS2 3516/4885ALDH1A1 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.